Nomenclature	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507	http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=508
HGNC, UniProt	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:12716, http://www.uniprot.org/uniprot/Q8NER1	https://www.genenames.org/data/gene‐symbol‐report/#!/hgnc_id/HGNC:18082, http://www.uniprot.org/uniprot/Q9Y5S1
Other chemical activators	NO‐mediated cysteine S‐nitrosylation	–
Physical activators	depolarization (V½ 0 mV at 35°C), noxious heat (> 43°C at pH 7.4)	–
Endogenous activators	extracellular http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2346 (at 37°C) (pEC50 5.4), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2481 (Agonist) (pEC50 5.1) [‐60mV] [http://www.ncbi.nlm.nih.gov/pubmed/10823958?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2364 (pEC50 5) [http://www.ncbi.nlm.nih.gov/pubmed/12761211?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2487 (Agonist) (pEC50 4.9) [‐60mV] [http://www.ncbi.nlm.nih.gov/pubmed/10823958?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3390	–
Activators	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2491 (Agonist) (pEC50 8.4) [physiological voltage] [http://www.ncbi.nlm.nih.gov/pubmed/11301059?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2486 (Agonist) (pEC50 7.5) [‐100mV – 160mV] [http://www.ncbi.nlm.nih.gov/pubmed/15306801?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2489 (Agonist) (pEC50 4.4–5) [‐70mV] [http://www.ncbi.nlm.nih.gov/pubmed/15685214?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2422, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2494, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4283 [http://www.ncbi.nlm.nih.gov/pubmed/15356216?dopt=AbstractPlus]	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433 (pEC50 5) [http://www.ncbi.nlm.nih.gov/pubmed/17395593?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/18550765?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2424 (pEC50 4.8) [http://www.ncbi.nlm.nih.gov/pubmed/18550765?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4150 (pEC50 4.5) [http://www.ncbi.nlm.nih.gov/pubmed/18550765?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4357 (pEC50 4.5) [http://www.ncbi.nlm.nih.gov/pubmed/17850966?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2433 (Agonist) (pEC50 3.8–3.9) [physiological voltage] [http://www.ncbi.nlm.nih.gov/pubmed/15194687?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17673572?dopt=AbstractPlus] – Mouse, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2494 (Agonist) Concentration range: 1×10−4M [‐80mV] [http://www.ncbi.nlm.nih.gov/pubmed/15722340?dopt=AbstractPlus, http://www.ncbi.nlm.nih.gov/pubmed/17673572?dopt=AbstractPlus] – Mouse
Selective activators	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2488 (Agonist) (pEC50 7.7) [physiological voltage] [http://www.ncbi.nlm.nih.gov/pubmed/11301059?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4178 (pEC50 6.6) [physiological voltage] [http://www.ncbi.nlm.nih.gov/pubmed/20510930?dopt=AbstractPlus] – Rat	–
Channel blockers	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4109 (pIC50 8.4), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4110 (pIC50 8), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6347 (Inhibition) (pIC50 7.8) [physiological voltage] [http://www.ncbi.nlm.nih.gov/pubmed/15615864?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2460 (Antagonist) (pIC50 7.5) [http://www.ncbi.nlm.nih.gov/pubmed/24055075?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2461 (Antagonist) (pIC50 7.4) [‐60mV] [http://www.ncbi.nlm.nih.gov/pubmed/11226139?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432 (pIC50 6.7–7)	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2432 (pIC50 6.2), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4331 (Inhibition) Concentration range: 5×10−4M [http://www.ncbi.nlm.nih.gov/pubmed/17673572?dopt=AbstractPlus] – Mouse
Selective channel blockers	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4129 (pIC50 9) [http://www.ncbi.nlm.nih.gov/pubmed/20307063?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4130 (pIC50 8.4) [http://www.ncbi.nlm.nih.gov/pubmed/17585751?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4117 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/15837819?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4120 (pIC50 8.3) [http://www.ncbi.nlm.nih.gov/pubmed/17660385?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4309 (pIC50 8.2) [http://www.ncbi.nlm.nih.gov/pubmed/14654105?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4230 (Antagonist) (pIC50 8) [http://www.ncbi.nlm.nih.gov/pubmed/12237342?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4228 (Antagonist) (pIC50 7.8) [physiological voltage] [http://www.ncbi.nlm.nih.gov/pubmed/15771431?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4310 (Antagonist) (pK B 7.7), http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4311 (Antagonist) (pIC50 7.1) [http://www.ncbi.nlm.nih.gov/pubmed/17392405?dopt=AbstractPlus]	–
Labelled ligands	http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4076 (Channel blocker) (pK d 8.5) [http://www.ncbi.nlm.nih.gov/pubmed/17660385?dopt=AbstractPlus], http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2492 (Channel blocker, Antagonist) (pIC50 8.4) [‐50mV] [http://www.ncbi.nlm.nih.gov/pubmed/11125018?dopt=AbstractPlus] – Rat, http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4091 (Activator)	–
Functional Characteristics	γ = 35 pS at – 60 mV; 77 pS at + 60 mV, conducts mono and di‐valent cations with a selectivity for divalents (PCa/PNa = 9.6); voltage‐ and time‐ dependent outward rectification; potentiated by ethanol; activated/potentiated/upregulated by PKC stimulation; extracellular acidification facilitates activation by PKC; desensitisation inhibited by PKA; inhibited by Ca2+/ calmodulin; cooling reduces vanilloid‐evoked currents; may be tonically active at body temperature	Conducts mono‐ and di‐valent cations (PCa/PNa = 0.9–2.9); dual (inward and outward) rectification; current increases upon repetitive activation by heat; translocates to cell surface in response to IGF‐1 to induce a constitutively active conductance, translocates to the cell surface in response to membrane stretch